

# Dean C Singleton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3374710/publications.pdf>

Version: 2024-02-01

7  
papers

442  
citations

1684188

5  
h-index

1872680

6  
g-index

10  
all docs

10  
docs citations

10  
times ranked

744  
citing authors

#	ARTICLE	IF	CITATIONS
1	Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411NTR leading to therapeutic benefit. <i>Cancer Gene Therapy</i> , 2022, 29, 1021-1032.	4.6	4
2	Therapeutic targeting of the hypoxic tumour microenvironment. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 751-772.	27.6	185
3	Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer. <i>BMC Cancer</i> , 2020, 20, 470.	2.6	21
4	Hypoxia-Activated Prodrugs of PERK Inhibitors. <i>Chemistry - an Asian Journal</i> , 2019, 14, 1238-1248.	3.3	10
5	Transcriptional up-regulation of ULK1 by ATF4 contributes to cancer cell survival. <i>Biochemical Journal</i> , 2013, 449, 389-400.	3.7	128
6	Bystander or No Bystander for Gene Directed Enzyme Prodrug Therapy. <i>Molecules</i> , 2009, 14, 4517-4545.	3.8	91
7	In vitro breast cancer models for studying mechanisms of resistance to endocrine therapy. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 297-320.	0.8	3